Table 2.
Patient characteristics prior to the study after classification of TRACP-5b values, and L-BMD and H-BMD values at 0, 4, 8, and 12 months of denosumab treatment
| Characteristic | TRACP-5b (<420 mU/dL) (n=47) |
TRACP-5b (≥420 mU/dL) (n=51) |
p-value |
|---|---|---|---|
| Age (years) | 73.2±8.5 | 74.1±8.8 | 0.59 |
| BMI (kg/m2) | 22.0±3.7 | 21.5±4.2 | 0.52 |
| Serum BAP (µg/L) | 11.8±4.6 | 21.3±8.4 | <0.001 |
| Serum TRACP-5b (mU/dL) | 283.9±99.3 | 683.3±197.5 | <0.001 |
| BP pretreatment, n | 32 | 7 | |
| Duration of BP use, years | 2.9±2.5 | 9.9±8.3 | 0.20 |
| PTH combination, n | 19 | 25 | |
| L-BMD (g/cm2) at 0 months | 0.796±0.11 | 0.783±0.17 | 0.64 |
| H-BMD (g/cm2) at 0 months | 0.664±0.10 | 0.640±0.10 | 0.24 |
| L-BMD (g/cm2) at 4 months | 0.825±0.10 | 0.830±0.10 | 0.83 |
| H-BMD (g/cm2) at 4 months | 0.666±0.07 | 0.656±0.10 | 0.63 |
| L-BMD (g/cm2) at 8 months | 0.832±0.09 | 0.839±0.10 | 0.75 |
| H-BMD (g/cm2) at 8 months | 0.674±0.10 | 0.665±0.10 | 0.71 |
| L-BMD (g/cm2) at 12 months | 0.850±0.11 | 0.854±0.11 | 0.88 |
| H-BMD (g/cm2) at 12 months | 0.680±0.10 | 0.668±0.10 | 0.59 |
Notes: Results are expressed as mean ± standard deviation. p<0.05 was considered statistically significant.
Abbreviations: BAP, bone alkaline phosphatase; BMD, bone mineral density; BMI, body mass index; BP, bisphosphonate; H-BMD, total hip BMD; L-BMD, lumbar 1–4 BMD; PTH, teriparatide; TRACP-5b, tartrate-resistant acid phosphatase 5b.